<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3141">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04325906</url>
  </required_header>
  <id_info>
    <org_study_id>COVID-19-HFNC+PP</org_study_id>
    <nct_id>NCT04325906</nct_id>
  </id_info>
  <brief_title>Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS</brief_title>
  <official_title>Early Prone Positioning Combined With High-Flow Nasal Cannula Versus High-Flow Nasal Cannula in COVID-19 Induced Moderate to Severe ARDS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rush University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rush University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Coronavirus disease 2019 (COVID-19) is an emerging infectious disease that was first reported
      in Wuhan, China, and had subsequently spread worldwide. Twenty-nine percent of COVID-19
      patients may develop ARDS. Based on the potential beneficial mechanisms of HFNC and PP,
      whether early use of prone positioning combined with HFNC can avoid the need for intubation
      in COVID-19 induced moderate to severe ARDS patients needs to be further investigated.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment failure</measure>
    <time_frame>28 days</time_frame>
    <description>the treatment failure rate of HFNC/HFNC+PP support and clinical requirement for advanced respiratory support</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intubation rate</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of PP</measure>
    <time_frame>28 days</time_frame>
    <description>the improvement of SpO2/FIO2 or PaO2/FiO2 from HFNC alone to HFNC+PP</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">346</enrollment>
  <condition>Prone Positioning</condition>
  <condition>High Flow Nasal Cannula</condition>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <condition>Corona Virus Infection</condition>
  <arm_group>
    <arm_group_label>high flow nasal cannula only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Receive high flow nasal cannula only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HFNC plus prone positioning</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receive high flow nasal cannula plus prone positioning</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>high flow nasal cannula (HFNC)</intervention_name>
    <description>HFNC will be initiated at 50 L/min (AIRVO2 or Optiflow, Fisher &amp;Paykel Health care Limited., Auckland, New Zealand) with temperature set at 37 oC. Nasal cannula size will be determined by the patient's nostril size (≤ 50%). FIO2 will be adjusted to maintain SpO2 at 92% to 95%. Flow and temperature will be adjusted based on patient's comfort and clinical response.</description>
    <arm_group_label>HFNC plus prone positioning</arm_group_label>
    <arm_group_label>high flow nasal cannula only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Prone positioning (PP)</intervention_name>
    <description>PP will be performed before or 1 hour after meal. Before PP, all the I.V. lines and nasal cannula will be checked by clinicians. PP will be performed by patient under the supervision of clinicians. Assistance will be offered if needed. If tolerated, PP will be maintained for at least 30 minutes, until the patients feel tired to keep that position. PP will be performed twice a day for the first 3 days after the patient's enrollment. FIO2 will be adjusted to maintain SpO2 at 92-95%.</description>
    <arm_group_label>HFNC plus prone positioning</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  COVID-19 induced adult ARDS patients admitted to the medical ICU

          -  PaO2/FiO2 is less than 200mmHg or FIO2 ≥ 0.4 is required to maintain SpO2 at 88-93% on
             HFNC treatment

        Exclusion Criteria:

          1. If the patients have a consistent SpO2&lt;80% when on evaluation with a FiO2 of 0.6, or
             signs of respiratory fatigue (RR &gt; 40/min, PaCO2&gt; 50mmHg / pH&lt;7.30, and obvious
             accessory respiratory muscle use);

          2. Immediate need for intubation (PaO2/FiO2&lt; 50mmHg or SpO2/FiO2 &lt;90, unable to protect
             airway or mental status change);

          3. unstable hemodynamic status(SBP&lt;90mmHg, MBP below 65 mmHg or requirement for
             vasopressor);

          4. unable to collaborate with HFNC/PP with agitation or refuse HFNC/PP.

          5. chest trauma or any contraindication for PP

          6. pneumothorax

          7. age &lt; 18 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jie Li, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rush University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jie Li, PhD</last_name>
    <phone>312-947-0065</phone>
    <email>Jie_Li@rush.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jie Li, PhD</last_name>
      <phone>312-947-0065</phone>
    </contact>
    <investigator>
      <last_name>Sara Mirza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Vines, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jie Li, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Guérin C, Reignier J, Richard JC, Beuret P, Gacouin A, Boulain T, Mercier E, Badet M, Mercat A, Baudin O, Clavel M, Chatellier D, Jaber S, Rosselli S, Mancebo J, Sirodot M, Hilbert G, Bengler C, Richecoeur J, Gainnier M, Bayle F, Bourdin G, Leray V, Girard R, Baboi L, Ayzac L; PROSEVA Study Group. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med. 2013 Jun 6;368(23):2159-68. doi: 10.1056/NEJMoa1214103. Epub 2013 May 20.</citation>
    <PMID>23688302</PMID>
  </reference>
  <reference>
    <citation>Ding L, Wang L, Ma W, He H. Efficacy and safety of early prone positioning combined with HFNC or NIV in moderate to severe ARDS: a multi-center prospective cohort study. Crit Care. 2020 Jan 30;24(1):28. doi: 10.1186/s13054-020-2738-5.</citation>
    <PMID>32000806</PMID>
  </reference>
  <reference>
    <citation>Munshi L, Del Sorbo L, Adhikari NKJ, Hodgson CL, Wunsch H, Meade MO, Uleryk E, Mancebo J, Pesenti A, Ranieri VM, Fan E. Prone Position for Acute Respiratory Distress Syndrome. A Systematic Review and Meta-Analysis. Ann Am Thorac Soc. 2017 Oct;14(Supplement_4):S280-S288. doi: 10.1513/AnnalsATS.201704-343OT. Review.</citation>
    <PMID>29068269</PMID>
  </reference>
  <reference>
    <citation>Scholten EL, Beitler JR, Prisk GK, Malhotra A. Treatment of ARDS With Prone Positioning. Chest. 2017 Jan;151(1):215-224. doi: 10.1016/j.chest.2016.06.032. Epub 2016 Jul 8. Review.</citation>
    <PMID>27400909</PMID>
  </reference>
  <reference>
    <citation>Respiratory care committee of Chinese Thoracic Society. [Expert consensus on preventing nosocomial transmission during respiratory care for critically ill patients infected by 2019 novel coronavirus pneumonia]. Zhonghua Jie He He Hu Xi Za Zhi. 2020 Feb 20;17(0):E020. doi: 10.3760/cma.j.issn.1001-0939.2020.0020. [Epub ahead of print] Chinese.</citation>
    <PMID>32077661</PMID>
  </reference>
  <reference>
    <citation>Frat JP, Thille AW, Mercat A, Girault C, Ragot S, Perbet S, Prat G, Boulain T, Morawiec E, Cottereau A, Devaquet J, Nseir S, Razazi K, Mira JP, Argaud L, Chakarian JC, Ricard JD, Wittebole X, Chevalier S, Herbland A, Fartoukh M, Constantin JM, Tonnelier JM, Pierrot M, Mathonnet A, Béduneau G, Delétage-Métreau C, Richard JC, Brochard L, Robert R; FLORALI Study Group; REVA Network. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med. 2015 Jun 4;372(23):2185-96. doi: 10.1056/NEJMoa1503326. Epub 2015 May 17.</citation>
    <PMID>25981908</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>March 26, 2020</study_first_submitted>
  <study_first_submitted_qc>March 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2020</study_first_posted>
  <last_update_submitted>October 5, 2020</last_update_submitted>
  <last_update_submitted_qc>October 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

